# Genome BC Genome BC is an Endowment / Foundation based in Vancouver, Canada. ## Overview - **Organization type:** Endowment / Foundation - **Headquarters:** Vancouver, Canada - **Region:** North America - **Address:** 400-575 West 8th Avenue, Vancouver, BC V5Z 0C4, Canada - **Founded:** 2000 - **Assets under management:** Undisclosed - **Website:** genomebc.ca - **LinkedIn:** https://ca.linkedin.com/company/genome-british-columbia ## Regulatory record - **Reports private funds:** No ## About Genome BC was founded in 2000 as a not-for-profit catalyst for genomics innovation in British Columbia. President and CEO Suzanne Gill leads an organization that bridges academic research and industrial application, co-funded by Genome Canada and the Province of British Columbia. Its mandate spans seven sectors, applying genomics to challenges in health, forestry, fisheries, agriculture, energy, mining, and the environment. The organization deploys capital across early-stage and venture opportunities through a hybrid model of research grants and direct commercialization support. Its investment posture translates genomic discoveries into applied solutions — spanning digital health diagnostics, climate-resilient agriculture, and microbial tools for mining and energy remediation. Key research partners include the University of British Columbia (UBC), the University of Victoria, and the Michael Smith Genome Sciences Centre. Recent work has targeted areas like precision oncology and sustainable forestry genomics. Gill oversees the foundation's strategic direction alongside Board Chair Peggy Johnston and CFO Tony Brooks, who also leads the Entrepreneurship & Commercialization portfolio. Genome BC operates from its Vancouver headquarters, with a specialized research footprint at the UVic-Genome BC Proteomics Centre in Victoria. The organization is embedded in the provincial innovation ecosystem through active memberships in LifeSciences BC and the Greater Vancouver Board of Trade. In 2023, Genome Canada and provincial partners renewed multi-year funding commitments to sustain national genomics platforms (per Genome Canada, 2023). Genome BC's structural differentiation lies in its role as a public-purpose venture catalyst rather than a return-seeking institutional investor. It operates on a co-funding mandate with federal and provincial governments, absorbing early-stage scientific risk to de-risk opportunities for later industrial adoption. This model links academic labs directly with industry through a single, regionally focused funding platform — a governance structure distinct from both pure grant-making bodies and private venture firms. ## Sectors - Digital Health - AgriTech & FoodTech - ClimateTech - Energy Transition & Renewables ## Offices - Victoria, BC, Canada ## People - Suzanne Gill — President and CEO - Peggy Johnston — Chair of the Board of Directors - Tony Brooks — CFO and VP, Entrepreneurship & Commercialization ## Questions ### Who runs investment decisions at Genome BC? President and CEO Suzanne Gill leads the organization's strategic and investment direction, supported by CFO and VP of Entrepreneurship & Commercialization Tony Brooks. The Board of Directors, chaired by Peggy Johnston, provides governance oversight. Investment decisions follow a co-funding model with federal and provincial partners Genome Canada and the Province of British Columbia. ### How does Genome BC source its deal flow? Deal flow originates through academic partnerships with institutions like the University of British Columbia, the University of Victoria, and the Michael Smith Genome Sciences Centre. As a regional catalyst, Genome BC identifies high-potential genomics research projects and entrepreneurial ventures within British Columbia's life sciences ecosystem, often co-funded with Genome Canada. ### Which sectors does Genome BC explicitly avoid? Genome BC's mandate is focused on applying genomics to seven sectors: human health, agriculture, forestry, fisheries, energy, mining, and the environment. It does not invest in unrelated technology verticals such as enterprise software, fintech, or consumer internet, and its scope is bounded by the province of British Columbia. ### How does Genome BC structure its investments? Genome BC uses a mix of research grants and direct commercialization support, deploying capital into early-stage and venture-stage genomics projects. It does not make fund commitments as a limited partner. The organization co-invests alongside Genome Canada and the Province of British Columbia to de-risk scientific ventures for eventual industrial adoption. ## Related profiles - [The John and Mary Corcoran Family Foundation](https://altss.com/profile/the-john-and-mary-corcoran-family-foundation) - [Anchor Hanover](https://altss.com/profile/anchor-hanover) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/genome-bc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology